February 19, 2022
Article
“These data support further evaluation of antibody-drug conjugate/checkpoint inhibitor combination [therapy] in metastatic urothelial cancer in the platinum-refractory setting and probably in earlier lines of therapy in a different patient population,” says Petros Grivas, MD, PhD.
November 02, 2021
Article
A phase 2a efficacy analysis has been launched exploring the combination of the novel oral immune activator BXCL701 and pembrolizumab in prostate cancer patients with de novo or treatment-emergent small cell neuroendocrine carcinoma.
September 18, 2021
Article
Additional prospective trials containing a larger sample size and longer follow up are needed to determine the optimal treatment sequence in favorable-risk advanced renal cell carcinoma.
August 13, 2021
Article
The FDA has officially released its finalized recommendation for the use of metastases-free survival as an end point in clinical trials evaluating treatments for patients with nonmetastatic castration-resistant prostate cancer.